GHP Investment Advisors’s Accelerate Diagnostics AXDX Stock Holding History

GHP Investment Advisors’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-100	Closed	-$71	–	948
2025 Q1	$71	Hold	100	–	–	﹤0.01%	943
2024 Q4	$120	Hold	100	–	–	﹤0.01%	965
2024 Q3	$171	Hold	100	–	–	﹤0.01%	953
2024 Q2	$117	Hold	100	–	–	﹤0.01%	955
2024 Q1	$99	Hold	100	–	–	﹤0.01%	827
2023 Q4	$392	Hold	100	–	–	﹤0.01%	815
2023 Q3	$588	Buy	100 +90	+900%	+$606	﹤0.01%	904
2023 Q2	$705	Sell	10 -90	-90%	-$676	﹤0.01%	885
2023 Q1	$700	Hold	100	–	–	﹤0.01%	874
2022 Q4	$706	Hold	100	–	–	﹤0.01%	882
2022 Q3	$2K	Hold	100	–	–	﹤0.01%	823
2022 Q2	$1K	Hold	100	–	–	﹤0.01%	872
2022 Q1	$1K	Buy	+100	New	+$2.85K	﹤0.01%	909

Other funds holding AXDX

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

BCWM

Bartlett & Co Wealth Management Cincinnati, Ohio $7.82B AUM 15.4% 1-Year Est. Return

GHP Investment Advisors's AXDX Position: Q2 2025 in Review

GHP Investment Advisors sold out of Accelerate Diagnostics (AXDX) in Q2 2025, closing a stake of 100 shares — an estimated $71 sold.

GHP Investment Advisors first reported a position in AXDX in Q1 2022 and held it in 13 quarters. The position peaked at $2K in Q3 2022. 3 funds tracked by Wall St. Rank hold AXDX as of Q2 2025.

GHP Investment Advisors reported no remaining Accelerate Diagnostics position as of Q2 2025 after selling out during the quarter.
GHP Investment Advisors sold 100 Accelerate Diagnostics shares in Q2 2025, an estimated $71.
GHP Investment Advisors first reported a position in Accelerate Diagnostics in Q1 2022 and held it in 13 quarters.
GHP Investment Advisors's Accelerate Diagnostics position peaked at $2K in Q3 2022.
3 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2025.

Based on GHP Investment Advisors's 13F filing for Q2 2025, filed 5 Aug 2025.